{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:45:22Z","timestamp":1793249122078,"version":"4.5.0"},"reference-count":25,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Graves' disease (GD) is the most common cause of thyrotoxicosis. Medical therapy with methimazole is the most common way to treat GD, but it has a narrow and dynamic therapeutic index, requiring frequent monitoring for titration. It is unclear how much initial disease severity (IDS) affects titration patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Identify associations between IDS with methimazole dose and thyrotoxicosis control after initiation of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective longitudinal cohort study (2018-2024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>A single tertiary medical center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients or Other Participants<\/jats:title>\n                    <jats:p>The study included 152 patients, aged 18 years and older, diagnosed with GD. It encompassed 1432 encounters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measure(s)<\/jats:title>\n                    <jats:p>The analysis focused on the association of IDS, age, and sex with average decrease in methimazole dose per encounter, biochemical thyroid status per encounter, time until first euthyroid encounter, and dose of methimazole after 180 days of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IDS was positively associated with percentage dose reduction of methimazole per encounter (P = .012) and proportion of hypothyroid encounters (P = .0101). There was no association of IDS with the proportion of hyperthyroid encounters (P = .088), methimazole dose after 180 days (P = .222), nor time to first encounter with euthyroid status. Age and sex were not associated with changes in dose or biochemical thyroid status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>When given a larger dose of methimazole, patients with severe thyrotoxicosis from GD reach euthyroid status as quickly as other patients with GD. However, these patients have more lability in thyroid control and may benefit from more frequent monitoring. After 6 months, severity of initial thyrotoxicosis was not associated with methimazole dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag134","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:42:14Z","timestamp":1774356134000},"page":"2548-2556","source":"Crossref","is-referenced-by-count":1,"title":["Initial disease severity and methimazole titration for Graves' disease: a retrospective longitudinal cohort study"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-8836","authenticated-orcid":false,"given":"Aaron Hayden","family":"Smith","sequence":"first","affiliation":[{"name":"Indiana University School of Medicine Department of Medicine, Division of Endocrinology and Metabolism, , Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelina","family":"Priscu","sequence":"additional","affiliation":[{"name":"Franciscan Health Indianapolis Department of Medicine, Division of Endocrinology and Metabolism, , Indianapolis, IN 46237, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5531-4416","authenticated-orcid":false,"given":"Michael","family":"Morkos","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine Department of Medicine, Division of Endocrinology and Metabolism, , Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"5","key":"2026081219572893000_dgag134-B1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2026081219572893000_dgag134-B2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/cen.12060","article-title":"Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003\u20132005","volume":"78","author":"Nystr\u00f6m","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"16","key":"2026081219572893000_dgag134-B3","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2026081219572893000_dgag134-B4","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1210\/clinem\/dgae222","article-title":"A 2023 international survey of clinical practice patterns in the management of Graves disease: a decade of change","volume":"109","author":"Villagelin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026081219572893000_dgag134-B5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with Graves' disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"issue":"2","key":"2026081219572893000_dgag134-B6","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1210\/clinem\/dgaf433","article-title":"Impact of minimal dose strategy before antithyroid drug discontinuation on relapse risk in Graves' disease","volume":"111","author":"Miyamura","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026081219572893000_dgag134-B7","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A 2011 survey of clinical practice patterns in the management of Graves' disease","volume":"97","author":"Burch","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026081219572893000_dgag134-B8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","article-title":"Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study","volume":"49","author":"Benker","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026081219572893000_dgag134-B9","volume-title":"Methimazole\u2014StatPearls\u2014NCBI Bookshelf","author":"Awosika","year":"2023"},{"issue":"4","key":"2026081219572893000_dgag134-B10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S2213-8587(19)30059-2","article-title":"Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study","volume":"7","author":"Okosieme","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"2026081219572893000_dgag134-B11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198411223112106","article-title":"Antithyroid drugs","volume":"311","author":"Cooper","year":"1984","journal-title":"N Engl J Med"},{"key":"2026081219572893000_dgag134-B12","doi-asserted-by":"crossref","first-page":"2619695","DOI":"10.1155\/2017\/2619695","article-title":"Efficacy of once daily versus divided daily administration of low daily dosage (15 mg\/day) of methimazole in the induction of euthyroidism in Graves' hyperthyroidism: a randomized controlled study","volume":"2017","author":"Sriussadaporn","year":"2017","journal-title":"Int J Endocrinol"},{"key":"2026081219572893000_dgag134-B13","author":"Priscu"},{"issue":"6","key":"2026081219572893000_dgag134-B14","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1210\/jc.2009-2495","article-title":"Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study","volume":"95","author":"Boelaert","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026081219572893000_dgag134-B15","first-page":"206","article-title":"An effective straightforward protocol for the treatment of Graves' hyperthyroidism for primary care providers","volume":"7","author":"Eugenio","year":"2023","journal-title":"Curr Trends Intern Med"},{"key":"2026081219572893000_dgag134-B16","first-page":"18","article-title":"Hypothyroidism conversion to hyperthyroidism: it's never too late","volume":"2018","author":"Ahmad","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"1","key":"2026081219572893000_dgag134-B17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/thy.2012.0374","article-title":"Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa","volume":"23","author":"McLachlan","year":"2013","journal-title":"Thyroid"},{"issue":"5","key":"2026081219572893000_dgag134-B18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eprac.2024.02.001","article-title":"Using bedside spectral Doppler ultrasound for the assessment of patients with thyrotoxicosis","volume":"30","author":"Morkos","year":"2024","journal-title":"Endocr Pract"},{"issue":"1-3","key":"2026081219572893000_dgag134-B19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0378-4274(01)00539-2","article-title":"Extrathyroidal actions of antithyroid thionamides","volume":"128","author":"Bandyopadhyay","year":"2002","journal-title":"Toxicol Lett"},{"issue":"5","key":"2026081219572893000_dgag134-B20","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0026-895X(24)12506-0","article-title":"Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-\u03b3 signaling and H2O2 scavenging","volume":"60","author":"Kim","year":"2001","journal-title":"Mol Pharmacol"},{"key":"2026081219572893000_dgag134-B21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fendo.2020.00286","article-title":"Pharmacodynamic response to anti-thyroid drugs in Graves' hyperthyroidism","volume":"11","author":"Abbara","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2026081219572893000_dgag134-B22","doi-asserted-by":"crossref","first-page":"e1914","DOI":"10.1210\/clinem\/dgaf503","article-title":"Low-dose methimazole in the long-term management of Graves' disease: small doses, big benefits","volume":"111","author":"Villagelin","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081219572893000_dgag134-B23","first-page":"258","article-title":"Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells","volume":"74","author":"Karlsson","year":"1988","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"2026081219572893000_dgag134-B24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eprac.2024.12.011","article-title":"A predictive model for Graves' disease recurrence after antithyroid drug therapy: a retrospective multicenter cohort study","volume":"31","author":"Kawkgi","year":"2025","journal-title":"Endocr Pract"},{"issue":"9","key":"2026081219572893000_dgag134-B25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1089\/thy.2020.0881","article-title":"Does age or sex relate to severity or treatment prognosis in Graves' disease?","volume":"31","author":"Suzuki","year":"2021","journal-title":"Thyroid"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag134\/67554955\/dgag134.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/9\/2548\/67554955\/dgag134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/9\/2548\/67554955\/dgag134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:57:43Z","timestamp":1786579063000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/9\/2548\/8542011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,26]]},"published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag134","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,26]]}}}